Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) told investors that it believes the company has "maximized" its intellectual property (IP) position around DMT for stroke because it included so-called novel salt forms of the psychedelic compound in its recent patent applications.
The drug repurposing company is researching AP-188 (N,N-Dimethyltryptamine, or DMT) as a potential treatment for the rehabilitation of stroke.
A novel salt form of a drug is a new and separate structure from the original compound and is considered a new 'composition of matter'.
READ: Algernon Pharmaceuticals files for Clinical Trial and Ethics Approval for Phase 1 DMT human stroke study
Many drug compounds’ core structures can often be paired with a salt. Different salts can improve the core drug in several ways, including improved efficacy, safety/tolerability, and stability, explained Algernon.
The company said it has filed patent applications for new novel salt forms, as well as dosing, formulation, and method of use patent applications for stroke rehabilitation.
N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.
Several preclinical studies have demonstrated that DMT helps mitigate tissue damage and promote neurogenesis as well as structural and functional neural plasticity, with significance.
Contact the writer at giles@proactiveinvestors.com